CD80 and myeloid sarcoma: Notably, in MS patients, the number of circulating B cells expressing CD80 is increased during relapse, and IFN-β 1b treatment reduces the number of circulating CD80-expressing B cells, suggesting a proinflammatory role of CD80 on B cells also in humans [37].